bioRxivCancer Biology
Rpl24Bst mutation suppresses colorectal cancer by promoting eEF2 phosphorylation via eEF2K
J. R. Knight, N. Vlahov, D. M. Gay, R. A. Ridgway, L. Faller, C. Proud, G. R. Mallucci, T. von der Haar, C. M. Smales, A. E. Willis, O. J. Sansom
Abstract
Increased protein synthesis supports the rapid proliferation associated with cancer. The Rpl24Bst mutant mouse reduces the expression of the ribosomal protein RPL24 and has been used to suppress translation and limit tumorigenesis in multiple mouse models of cancer. Here we show that Rpl24Bst also suppresses tumorigenesis and proliferation in a model of colorectal cancer with two common patient mutations, Apc and Kras. In contrast to previous reports, Rpl24Bst mutation has no effect on ribosomal subunit abundance but suppresses translation elongation through phosphorylation of eEF2, reducing protein synthesis by 40% in tumour cells. Ablating eEF2 phosphorylation in Rpl24Bst mutant mice by inactivating its kinase, eEF2K, completely restores the rates of elongation and protein synthesis. Furthermore, eEF2K activity is required for the Rpl24Bst mutant to suppress tumorigenesis. This work demonstrates that elevation of eEF2 phosphorylation is an effective means to suppress colorectal tumorigenesis with two driver mutations. This positions translation elongation as a therapeutic target in colorectal cancer, as well as other cancers where the Rpl24Bst mutation has a tumour suppressive effect in mouse models.
- organism: mouse
- assay: proteomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Slap restricts oncogenic Src-family kinase signaling to maintain colonic epithelial homeostasis
Dana Naim, Zouheir HOUHOU, … Serge Roche·eLifePeer-reviewed·Sep 8, 2026
- Small Molecule Activators of B56-PP2A Restore 4E-BP Expression and Function to Suppress Cap-dependent Translation in Cancer Cells
M. A. Lum, K. A. Jonas-Breckenridge, … J. D. Black·bioRxiv·May 24, 2022
- Aggressive KRAS mutations direct TGF-β response towards partial EMT in patient-derived colorectal cancer tumoroids
Theresia Mair, Philip König, … Gerda Egger·Molecular OncologyPeer-reviewed·Mar 11, 2025
- SETD2 regulates the methylation of translation elongation factor eEF1A1 in clear cell renal cell carcinoma
R. Hapke, L. Venton, … S. M. Haake·bioRxiv·Oct 26, 2020
- Increased mRNA translation delays lung adenocarcinoma initiation and exposes a therapeutic vulnerability to MEK inhibitors
Luis Pardo, Madeleine Moore, … Jim C. Norman·bioRxiv·Mar 19, 2025
- Loss-of-function cancer-associated mutations in the EIF4G2 non-canonical translation initiation factor
S. Meril, M. Bhalsen, … A. Kimchi·bioRxiv·Aug 22, 2023